Dr Christos Kyratsous

Regeneron Pharmaceuticals, United States of America

Presentation title: “Rapid selection, characterization and clinical development of fully-human antibodies against emerging infectious diseases”

Christos Kyratsous holds a PhD in Microbiology from Columbia University, College of Physicians and Surgeons. He joined Regeneron in 2011 and is now Vice President for Research, heading the pre-clinical Infectious Diseases research group and a technology development group focused on viral vector engineering. In his role, he oversees a diverse portfolio of anti-pathogen fully-human monoclonal antibodies and novel gene and cell therapies. His group’s projects include antibodies developed as part of Regeneron’s Rapid Response against emerging viruses, e.g. the antibodies against Ebola Virus that are currently under review by the FDA, and antibodies against SARS-CoV-2, that are currently in Phase II/III clinical testing.